Author:
James L Sherley,Michael P Daley,Renly A Dutton
Abstract
Specific quantification of therapeutic tissue stem cells (TSCs) is a major challenge. We recently described a computational simulation method for accurate and specific counting of TSCs. The method quantifies TSCs based on their unique asymmetric cell kinetics, which is rate-limiting for TSCs’ production of transiently-amplifying lineage-committed cells and terminally arrested cells during serial cell culture. Because of this basis, the new method is called kinetic stem cell (KSC) counting. Here, we report further validations of the specificity and clinical utility of KSC counting. First, we demonstrate its quantification of the expected increase in the hematopoietic stem cell (HSC) fraction of CD34+-selected preparations of human-mobilized peripheral blood cells, an approved treatment product routinely used for HSC transplantation therapies. Previously, we also used the KSC counting technology to define new mathematical algorithms with the potential for rapid determination of TSC-specific fractions without the need for serial culture. A second important HSC transplantation treatment, CD34+-selected umbilical cord blood (UCB) cells, was used to investigate this prediction. We show that, with an input of only simple population doubling time (PDT) data, the KSC counting-derived “Rabbit algorithms” can be used to rapidly determine the specific HSC fraction of CD34+-selected UCB cell preparations with a high degree of statistical confidence. The algorithms define the stem cell fraction half-life (SCFHL), a new parameter that projects stem cell numbers during expansion culture. These findings further validate KSC counting’s potential to meet the long-standing unmet need for a method to determine stem cell-specific dosage in stem cell medicine.
Publisher
Heighten Science Publications Corporation
Reference23 articles.
1. 1. Ivanovic Z. Hematopoietic stem cells in research and clinical applications: The "CD34 issue". World J Stem Cells. 2010 Apr 26;2(2):18-23. doi: 10.4252/wjsc.v2.i2.18. PMID: 21607112; PMCID: PMC3097920.
2. 2. Sherley JL. Principles for targeting adult tissue stem cells to achieve durable gene and gene-editing therapeutics. In: Appasani K, ed. Genome Editing and Engineering: From Talens, ZFN, and CRISPRs to Molecular Surgery. Cambridge: Cambridge University Press, 2018:285-300.
3. 3. Sherley JL. Dose determination for stem cell medicine: a need whose time has come. In: Atala A, Cetrulo C, Cetrulo K, Murphy SV, Taghizadeh R, eds. Perinatal Stem Cells: Research and Therapy. Amsterdam: Elsevier, 2018:383-397.
4. 4. Sherley JL. Stem cell therapy: resolving the mismatch. Pharmaceutical Manufacturing. 2018; 38-41.
5. 5. Sherley JL. Achieving dose standardization for the stem cell clinical trials industry. Operations 10:03, May 31, 2018; http://www.clinicaltrialsarena.com/news/operations/achieving-dose-standardization-for-the-stem-cell-clinical-trials-industry-6172126.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献